RSPI — Respirerx Pharmaceuticals Cashflow Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.73m
- $3.87m
Annual cashflow statement for Respirerx Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -2.59 | -2.12 | -4.3 | -3.14 | -2.1 |
Depreciation | |||||
Non-Cash Items | 0.317 | 0.19 | 1.25 | 0.357 | 0.49 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 1.85 | 1.44 | 2.54 | 1.83 | 1.47 |
Change in Prepaid Expenses | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -0.427 | -0.488 | -0.513 | -0.956 | -0.144 |
Financing Cash Flow Items | — | -0.03 | — | — | — |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0.376 | 0.471 | 0.497 | 0.957 | 0.143 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.052 | -0.017 | -0.016 | 0.001 | -0.001 |